The present disclosure relates to blankets for a patient in a healthcare facility and particularly, to warming blankets.
Pre-operative patients are generally nervous, agitated, or otherwise stressed. Providing comfort warming can improve patient satisfaction. Almost all hospitals use conventional cotton warming blankets preheated in warming cabinets to provide comfort to pre-operative patients. However, such blankets lose their heat within a couple of minutes. Caregivers and operating room managers have confirmed there is an unmet need in providing comfort warming to pre-operative patients.
Some hospitals may use disposable air-activated self-heating blankets to provide comfort warming for an extended period; the heat is typically generated by an exothermic reaction of iron powder oxidizing into rust—iron oxide (Fe2O3), although other elements have been used. However, the use of air-activated blankets is primarily limited to military, athletics, or emergency medical services. Moreover, air-activated blankets do not feel as comfortable as cotton, as they are typically made with synthetic nonwoven materials. There is also concern over the environmental impact from the disposal of large single-use air-activated blankets. Also air-activated blankets are generally expensive (typically over $15 per use).
The present disclosure includes one or more of the features recited in the appended claims and/or the following features which, alone or in any combination, may comprise patentable subject matter.
In one aspect of the disclosed embodiments, a warming device may include a first fabric layer having a weldable fabric. A second fabric layer may have a weldable fabric. The second fabric layer may be coupled to the first fabric layer so that the weldable fabric of the second fabric layer faces the weldable fabric of the first fabric layer to form a pocket. A phase change material may be enclosed in the pocket.
In some embodiments, the weldable fabric on the first fabric layer may be a thermoplastic urethane. The weldable fabric on the second fabric layer may be a thermoplastic urethane. The first fabric layer may be at least one of cotton or a cotton-polyester blend. The second fabric layer may be at least one of cotton or a cotton-polyester blend. It may be any fabric that is comfortable for direct contact with human skin, such as those commonly used in clothing. The fabric layers, the weldable fabrics, and the phase change material may be configured to withstand temperatures of at least 71 degrees Celsius.
It may be desired that the phase change material is at least one of a powder or a granulated material. The phase change material may be carbon paraffin. The phase change material may have a melting point between approximately 37° C. and 44° C. The phase change material may be mixed with a carrier. The carrier may be at least one of oil, gel, rubber, or other pliable material. The phase change material may be mixed with a conductive material. The conductive material may be at least one of carbon fibers, graphene, carbon nanotubules, conductive polymers, or the oil-based carrier medium.
Alternatively, or in addition to, the pocket may be formed by bonding the weldable fabrics. The pocket may be formed by radiofrequency welding of the weldable fabrics. The pocket may include a plurality of channels, the phase change material being enclosed in each of the plurality of channels.
It may be contemplated that the weldable fabric of the first fabric layer is laminated to an inner side of the first fabric layer. The weldable fabric of the second fabric layer may be laminated to an inner side of the second fabric layer. The weldable fabric of the first fabric layer may be interwoven with the first fabric layer. The weldable fabric of the second fabric layer may be interwoven with the second fabric layer.
It is possible that an insulative material is coupled to an outer side of the first fabric layer, or in between the person-facing fabric and the laminate. A heating element may be provided to melt the phase change material.
In some embodiments, the warming device is a blanket. The warming device may be a pad or a plurality of pads. At least one electrical cable may electrically couple the plurality of pads.
In another aspect of the disclosed embodiments, a warming blanket may include a pair of fabric layers coupled together to form a plurality of channels. A plastic coating may line each of the plurality of channels. A phase change material may be enclosed within each of the plurality of channels. The pair of fabric layers, the plastic coating, and the phase change material may be configured to withstand temperatures of 71 degrees Celsius.
In some embodiments, the plastic coating is a thermoplastic urethane. The pair of fabric layers may be at least one of cotton or a cotton-polyester blend. The phase change material may be at least one of a powder or a granulated material. It may be mixed with rubber or gel to form a soft, pliable homogenous material.
It may be desired that the pocket or plurality of channels are formed by bonding the plastic coating. The plurality of channels may be formed by radio-frequency or ultrasonic welding of the plastic coating.
It may be contemplated that the plastic coating is laminated to an inner side of each of the pair of fabric layers. The plastic coating may be interwoven with each of the pair of fabric layers.
In yet another aspect of the disclosed embodiments, a warming device may include an outer shell defining a pocket. An insulating material may be positioned on an outer surface of the outer shell. A phase change material may be positioned within the pocket. A carrier may be mixed with the phase change material. A conductive material may be mixed with the phase change material.
It may be contemplated that the outer shell is at least one of cotton or a cotton-polyester blend. The warming device may be a blanket. The warming device may be a pad or a plurality of pads. At least one electrical cable may electrically couple the plurality of pads.
In some embodiments, the phase change material may be at least one of a powder or a granulated material. The phase change material may be carbon paraffin. The phase change material may have a melting point between approximately 37° C. and 44° C. A heating element may be provided to melt the phase change material.
It may be desired that the carrier is at least one of an oil or gel. The conductive material may at least one of carbon fibers, graphene, carbon nanotubules, or conductive polymers.
In another aspect of the disclosed embodiments, a method of manufacturing a warming device includes forming a first weldable fabric on a first fabric layer, and forming a second weldable fabric on a second fabric layer. The first fabric layer may be positioned on the second fabric so that the first weldable fabric is positioned adjacent the second weldable fabric. The first weldable fabric may be welded to the second weldable fabric to form at least one channel having an open end. The at least one channel may be filled with a phase change material. The open end of the at least one channel may be welded.
In some embodiments, the steps of welding further may include radio-frequency welding or ultrasonic welding.
It may be desired that the method include forming a plurality of channels. Forming a plurality of channels may include forming a first plurality of channels having open ends on a first side of the warming device, and forming a second plurality of channels having open end on a second side of the warming device. The method may also include filling the first plurality of channels from the first side of the warming device, and welding the open ends on the first side of the warming device. The method may also include filling the second plurality of channels from the second side of the warming device, and welding the open ends on the second side of the warming device.
In yet a further aspect of the disclosed embodiments, a warming device includes a batting layer that may have a phase change material. The batting may have a patient side and an upper side. A hot melt fabric adhesive may be applied to the patient side and upper side of the batting. A first fabric layer may be adhered to the hot melt fabric on the patient side of the batting. The first fabric layer may have a phase change material integrated coating. An insulation layer may be adhered to the hot melt fabric on the upper side of the batting. A second fabric layer may be coupled to the insulation layer.
In some embodiments, the batting layer may include loosely-packed quilt batting.
Optionally, the first fabric layer may include microencapsulated phase change materials mixed into a fabric coating. The microencapsulated phase change materials may include a polymer shell coating around that maintains a solid appearance through phase changes between solid and liquid states. The microencapsulated phase change materials may have a temperature between 38 degrees Celsius and 44 degrees Celsius. The microencapsulated phase change materials may have a latent heat of over 200 KJ/kg.
It may be desired that a sealant be positioned between the patient side of the batting and the hot melt fabric, and a sealant be positioned between the upper side of the batting and the hot melt fabric. A sealant may be positioned between the first fabric layer and the hot melt fabric on the patient side of the batting.
It may be contemplated that the hot melt fabric is non-woven. The hot melt fabric may be formed from a powder.
Alternatively or in addition to, the first fabric layer may be formed from cotton. The first fabric layer may be formed from a poly fabric. The second fabric layer may be formed from cotton. The second fabric layer may be formed from a poly fabric.
Optionally, the insulation layer may be formed from polyester fiber.
Additional features, which alone or in combination with any other feature(s), such as those listed above and/or those listed in the claims, can comprise patentable subject matter and will become apparent to those skilled in the art upon consideration of the following detailed description of various embodiments exemplifying the best mode of carrying out the embodiments as presently perceived.
The detailed description particularly refers to the accompanying figures in which:
Although this disclosure refers to specific embodiments, it will be understood by those skilled in the art that various changes in form and detail may be made without departing from the subject matter set forth in the accompanying claims.
Referring to
The device 16 may be used by patients that are at risk of hypothermia, wherein a core temperature of the patient 14 is below 36° C. The patient 14 may be at risk for hypothermia because the patient's metabolic rate is reduced, the patient room 10 is cold, and/or the patient's protective vasoconstriction response is reduced. The device 16 also facilitates preventing milder reductions in core temperature, which may prolong recovery, prolong the patient's length of stay, increase a rate of infection, and/or increase cardiovascular issues. The device 16 is configured to maintain normothermia above 36° C. throughout a surgery and pre/post operation.
As discussed in more detail below, the device 16 is configured to retain its temperature for a greater period of time than a conventional warming blanket. For example, a conventional blanket that has been heated in a warming cabinet will typically retain its temperature for approximately one to two minutes. Because of the structure of the device 16, as described below, the device 16 may retain its temperature for at least fifteen minutes or longer.
As illustrated in
In some embodiments, the phase change material 42 may be carbon paraffin. The phase change material 42 has a melting point between 38° C. and 44° C. to allow the phase change material 42 to stay at that temperature when the device 16 is removed from the blanket warming cabinet and exposed to the human body which has an average skin temperature of 33 C 18. For example, 20-carbon paraffin has a melting point of approximately 36.7° C. 21-carbon paraffin has a melting point of approximately 40.2° C., and 22-carbon paraffin has a melting point of approximately 44° C. The phase change material 42 is configured to be charged in the warming cabinet 18 so that the phase change material 42 melts, i.e. changes phase. Generally, upon removing the device 16 from the blanket warming cabinet 18, the phase change material 42 needs to be higher than an average skin temperature of 33° C. in order to feel warm to the patient 14. A temperature of the device 16 in contact with the patient's skin cannot exceed 41° C. for over 15) minutes. By having a lower melting point than the temperature of the warming cabinet 18, the temperature of the phase change material change can drop when the device 16 is removed from the warming cabinet 18, which typically has a temperature of 54° C. This minimizes a risk of burning the patient and exceeding regulatory guidelines for heating human skin. In some embodiments, phase change materials with different melting points may be used to deliver different temperature levels to meet patient demand. For example, the three different phase change materials 42 may be heated to a warm temperature of 35° C., a warmer temperature of 38° C., or a hot temperature of 41° C., thereby providing a warm blanket, a warmer blanket, and a hot blanket. The phase change material 42 is selected to have a high latent heat, e.g. over 200 KJ/kg. The high latent heat enables the phase change material 42 to release heat at the melting temperature over a longer period of time. Additionally, the high latent heat enables the use of a smaller amount of phase change material 42, which minimizes a thickness, weight, and cost of the device 16. In some embodiments, the device 16 includes a charging element 44 (shown optionally in broken line). The charging element 44 may be powered to maintain the phase of the phase change material 42. A sensor and controller may be included to ensure the heater does not raise the PCM temperature above a specified level that would cause burning or exceeding regulatory limits. The charging element 44 may be electrically coupled to a power source.
The phase change material 42 may be enclosed in the device 16 in a non-toxic, non-flammable granular form or a powder form. Small particles allow the blanket 16 to retain shape and feel softer and more pliable to the patient 14 when the device 16 reaches room temperature and solid phase. The small particles also increase surface area and improve the conduction of heat to ensure consistent temperature profiles. Small particles are more easily mixable with carrier oils, intermixed with conductive materials, and integrated into gels, rubbers, etc. In some embodiments, the phase change material 42 may be a microencapsulated phase change material. In some embodiments, the phase change material 42 is an eutectic organic phase change material.
Referring to
Referring to
Line 112 illustrates a temperature of fabric layer 30 over time, wherein fabric layer 30 is positioned against the patient's skin. Upon positioning the device 16 on the patient 14 at minute zero 120, the temperature of fabric layer 30 is approximately 54° C. 54° C. is approximately the temperature of the fabric layer 30 when the device 16 is removed from the warming cabinet 18. The temperature will rapidly drop as the blanket is exposed to room temperature of around 20 to 25 C. The temperature of fabric layer 30 then decreases to approximately 37° C., which is the melting point of the PCM in the computer model. Over the next 45 minutes from minute zero 120 to point 122, fabric layer 30 maintains a temperature of approximately 37° C. Accordingly, the temperature of fabric layer 30 is retained for approximately 45 minutes. After 45 minutes the temperature of fabric layer 30 gradually decreases to approximately 27° C. at point 124.
Line 114 illustrates a temperature of the phase change material 42 over time. Upon positioning the device 16 on the patient 14 at minute zero 120, the temperature of phase change material 42 may be approximately 54° C. 54° C. is approximately the temperature of the phase change material 42 when the device 16 is removed from the warming cabinet 18. The temperature of phase change material 42 then decreases to approximately 37° C. Over the next 45 minutes from minute zero 120 to point 122; phase change material 42 gradually decreases in temperature to a temperature of approximately 35° C. Accordingly, the temperature of phase change material 42 is relatively retained for approximately 45 minutes. After 45 minutes the temperature of phase change material 42 gradually decreases to approximately 26° C. at point 124.
Line 116 illustrates a temperature of fabric layer 32 over time, wherein fabric layer 32 is positioned away from the patient's skin. Upon positioning the device 16 on the patient 14 at minute zero 120, the temperature of fabric layer 32 is approximately 54° C. 54° C. is approximately the temperature of the fabric layer 32 when the device 16 is removed from the warming cabinet 18. The temperature of fabric layer 32 then decreases to approximately 34° C. Over the next 45 minutes from minute zero 120 to point 122; fabric layer 32 gradually decreases in temperature to a temperature of approximately 31° C. Accordingly, the temperature of fabric layer 32 is relatively retained for approximately 45 minutes. After 45 minutes the temperature of fabric layer 32 gradually decreases to approximately 25° C. at point 124.
As illustrated in the graph 100, the device 16 retains its temperature for approximately 45 minutes, which is a greater length of time than the one to two minutes that a convention blanket will retain its temperature. Because the device 16 retains its temperature a temperature of the patient's skin is retained at approximately 38° C. for approximately 45 minutes. It should be noted that graph 100 illustrates the temperature of a device 16 that has been heated to approximately 54° C. In other embodiments, the device 16 may be heated to temperatures greater or less than 54° C. In any embodiment, regardless of the temperature of the device 16, the blanket is configured to retain its temperature for a period of time that is greater than the time that a conventional blanket will retain its temperature.
The device 16 is configured to maintain heat longer than a conventional cotton warming blanket, which may lose heat in one to two minutes. Caregivers and other staff can use the device 16 without making changes to their work processes. During preparation, the device 16 may be pre-heated in the warming cabinet 18 along with traditional cotton warming blankets. In some embodiments, the device 16 may be stored in an optional insulated container (not shown) after being removed from the warming cabinet and before use to minimize heat loss while waiting to use the device 16 on the patient 14. This insulated container may be stored at the bedside to maximize the convenience for the caregiver.
The device 16 maintains a cotton feel unlike other blankets that use synthetic materials such as non-wovens and plastics. Additionally, the heavier weight provides comfort for the patient 14. The temperature of the device 16 stays within a comfortable range without overheating or burning the patient 14. The device 16 also allows a similar workflow for both caregivers and housekeeping staff, and only one blanket needed at a time, resulting in fewer trips to the warming cabinet to replace cooled blankets. The device 16 is also reusable and can be laundered at up to at least 160° F.
The phase change material 160 is mixed with a pliable carrier 162, e.g. oil or a gel. Because the carrier 162 may have a low thermal conductivity, a conductive material 164 is also mixed with the phase change material 160 to enhance heat distribution. The conductive material 164 may include carbon fibers, graphene, carbon nanotubules, and/or conductive polymers; oil as a carrier may be sufficient as a thermally conductive material. The conductive material 164 may be powdered or chopped so that the conductive material 164 is conformable to the patient's body. Maintaining normothermia in a typically male generally requires approximately 120 Watts. With a typical heat fusion of 2.1 kJ/kg approximately seven pounds of phase change material 160 is required to maintain 120 Watts for four hours. Accordingly, in a 50% mixture of carrier 162 and phase change material 160, the device 150 weighs approximately 15 pounds. The device 150 may be altered based on the patient, e.g. male/female, patient weight, patient age. Additionally, the device 150 may be altered based on the length of the procedure being performed. As such, the weight and mixture concentrations of the device 150 may be altered.
An insulating material 170 is positioned on the outer shell 152. The insulating material 170 is positioned on one side of the outer shell 152. The insulating material 170 is positioned on the side of the outer shell 152 that is configured to be positioned away from the patient 14. In some embodiments, the insulating material 170 is a reflective material.
Referring to
Referring to
At block 308, each channel 64 is filled with phase change material 42. For example, the channels 64 are filled through the respective open end 66. That is the open end 66 may be positioned upward so that the phase change material 42 is gravity feed into the channels 64. Once the channels 64 are filled with phase change material 42, the open ends 66 of the channels 64 are welded closed. In some embodiments, the first plurality of channels 64 is filled with phase change material 42 and the respective open ends 66 are welded closed. The warming device 16 is then inverted so that the open ends 66 of the second plurality of channels 64 faces upward. The second plurality of channels 64 are then filled with the phase change material 42 and the respective open ends 66 of the second plurality of channels 64 are welded closed at block 310.
Referring to
The PCM integrated coating 426 permeates the first fabric layer 424 and the surface of the first fabric layer 424 on one side of the first fabric layer 424. The coated side 426 of the first fabric layer 424 may face inward away from the patient. Alternatively, the coated side 426 of the first fabric layer 424 may face the patient and contact the patient's skin to optimize the sensation of warmth due to an increased rate of heat transfer. The coating 426 has high breathability as measured by moisture vapor transmission rate (MVTR) to allow perspiration to escape and to minimize increases in humidity. The coating 426 may incorporate flame retardants as needed to meet flammability standards. The first fabric layer 424 is a loose weave with drape and hand comparable to knit cotton blankets used in hospitals. Alternatively, the first fabric layer 424 could be a conventional thermal blanket. Loose weave fabrics hold more coating than a tight weave, due to more space between fibers.
The first fabric layer 424 is preferably a cotton-polyester blend to improve durability of PCM coating which is water-soluble because the cotton is hydrophilic. The polyester improves durability of fabric. The first fabric layer 424 is approximately 70 inches wide and approximately 90 inches long, or the size of conventional thermal blankets. A larger size would allow wrapping of the blanket underneath body. Alternatively, to reduce costs, the PCM-coating width may be less than the blanket width. Rather than applying a coating 426 that only partially covers the fabric width, three sections may be stitched together. A middle section may be completely coated from edge to edge with a conventional coating method. Side sections may be uncoated and stitched together to middle section with stitching methods that hide the seam.
Microencapsulated PCMs 430 are mixed into the fabric coating 426. The microencapsulated PCMs have a polymer shell coating around a phase change material that maintains a solid appearance even through phase changes. A non-encapsulated PCM changes between solid and liquid states. Most microencapsulated PCMs are paraffins similar to candle wax. Microencapsulated PCMs 430 appear as a fine powder due to a very small particle size of approximately 20 microns. The microencapsulated PCMs 430 may be provided as a wet cake or liquid dispersion form that can be easily mixed into a water-based coating compound. Wet cake has smaller particles than dry powder, and is less expensive. The microencapsulated PCMs 430 are non-toxic and much less flammable than a non-encapsulated PCM. Thus, the need for flame retardants may be avoided.
The microencapsulated PCMs 430 have a phase change temperature between 38 degrees Celsius and 44 degrees Celsius. The PCMs 430 will hold the temperature around the phase change temperature as it cools from above to below that temperature. This is because energy is released as molecular bonds are broken as the PCM transitions from liquid to solid phase. The surface temperature of the warming blanket 400 in contact with the skin should not exceed 41 degrees Celsius, which is an IEC standard, but the contact surface temperature of the warming blanket 400 is lower than the PCM temperature due to layers such as fabrics and insulation liners limiting heat transfer. The blanket's contact surface temperature must be higher than average skin temperature to induce a sensation of warmth. A human body's average skin temperature is around 33 degrees Celsius, but rises toward the core temperature of 37 degrees Celsius when the body is well-insulated. It takes 60-90 minutes to reach this level without active warming, but the application of heat can accelerate this temperature increase, and even cause the skin temperature to rise above 37 degrees Celsius with a higher contact surface temperature.
A combination of PCM melting temperatures may be employed to smooth out the temperature gradient and improve patient comfort. The phase change temperature being lower than the blanket warming temperature of 54 degrees Celsius allows the warming blanket 400 to quickly cool to that temperature and thus reach the safe contact surface temperature of 41 degrees Celsius. Multiple phase change temperature options may be provided to meet varying user preferences such as warm (37 degrees Celsius), very warm (39 degrees Celsius), and hot (41 degrees Celsius). Alternative embodiments may include PCM temperatures lower than 38 degrees Celsius and higher than 44 degrees Celsius. It is possible to keep a patient comfortable with a higher PCM temperature than the ambient room temperature which is generally between 20 degrees Celsius and 25 degrees Celsius. Thus, a PCM temperature as low as 25 degrees Celsius may deliver comfort. It is possible to use a PCM temperature higher than 44 degrees Celsius and still deliver a contact surface temperature at or below the desired temperature of 41 degrees Celsius. This is made possible using low-thermal conductivity materials such as insulation and fabrics which have high insulation. The PCMs 430 should have a high latent heat, preferably over 200 KJ/kg. A high latent heat allows the blanket to feel warm over a longer duration. A high latent heat allows as smaller amount of PCM 430 to be used, which minimizes the thickness, weight, and cost of the warming blanket 400.
The fabric coating 426 is flexible to improve drape and hand of the fabric to improve customer acceptance. The fabric coating 426 is durable to retain PCM particles from being washed out in laundry cycles. Heat-retaining performance would be compromised if PCM particles 430 were washed out. A more durable coating 426 allows the warming blanket 400 to be used more often, and thus reduces its cost per use. The warming blanket 400 may be colored or otherwise marked to make it easily distinguished from conventional warming blankets. The warming blanket 400 may also have labels that minimize the likelihood it will be removed from the perioperative unit.
The batting layer 402 includes an inner liner of loosely-packed quilt batting that hold a larger mass of PCM coating than a thinner fabric that comes into direct contact with skin. The additional PCM facilitates improving the drape and hand of the warming blanket 400 by reducing the PCM mass that is coated onto the fabric in contact with the skin. The loosely-packed batting holds more coating/PCM than a tightly-woven fabric.
The insulation layer 440 above the phase change material facilitates minimizing heat loss to the ambient room environment, and thus allows the PCM to retain a higher temperature over a longer duration. The insulation layer 440 also reduces the mass of PCM needed which impacts weight, thickness, cost, and improves patient comfort. There is no insulation liner between the PCM and the human body because this would have the effect of lowering the contact surface temperature and thus compromising the feeling of warmth. In some embodiments, the insulation layer 440 may include Thinsulate® or Primaloft®. In some embodiments, the insulation layer 440 may be cotton, polyester, or cotton/poly thermal batting/interfacing. A thermal conductivity of the insulation layer may be approximately 0.04 W/m·K or less.
The hot melt fabric adhesive 422 is used to hold the PCM-coated quilt batting layer 402, insulation liner 440, and possibly other layers in place. The inner liners need to be fastened in place to prevent redistribution and bunching up, especially in laundry cycles. The hot melt fabric adhesive 422 is flexible to avoid negatively impacting drape and hand of fabric. The hot melt fabric adhesive 422 may be a powder or hot melt adhesives converted into a nonwoven fabric. Fire retardants may be mixed into the hot melt fabric adhesive 422 to optimize compliance to flammability codes and standards.
The sealant 420 facilitates increasing durability of the PCM-integrated coating 426. Additionally, a sealant 420 may be used to improve the durability of fabric coatings developed to retain PCM microcapsules 430 which typically have compromised durability due to the need to retain the fabric's drape and hand. The sealant 420 is applied directly to the coating 426 and, in some embodiments, mixed into the coating 426. In some embodiments, the hot melt fabric adhesive 422 may deliver the protection that would otherwise be provided by a sealant 420. Thus, in such embodiments, the sealant 420 may not be necessary where a fabric adhesive is able to provide this protection. The sealant 420 is highly breathable, with high MTVR, to facilitate minimizing humidity below the blanket.
Referring to
Referring to line 502, the patient's skin is approximately 33 degrees Celsius before the warming blanket 400 is applied at time 520. After applying the warming blanket 400 to the patient's skin, the temperature of the patient's skin increases to 39 degrees Celsius at time 522, which is approximately 2 minutes. The temperature of the patient's skin then drops to approximately 38 degrees Celsius for a time period 524 of approximately 45 minutes. After the time period 524, the temperature of the patient's skin begins to exponentially decrease to a temperature of approximately 28 degrees Celsius at time 526.
Referring to line 504, the first fabric layer 424 has a temperature of approximately 54 degrees Celsius at time 520 when the warming blanket is removed from the warming cabinet. After applying the warming blanket 400 to the patient, the temperature of the first fabric layer 424 decreases to approximately 38 degrees Celsius at time 522. This temperature is retained throughout the time period 524. After the time period 524, the temperature of the first fabric layer 424 exponentially decreases to a temperature of approximately 27 degrees Celsius at time 526.
Referring to line 506, the PCMs 430 have a temperature of approximately 54 degrees Celsius at time 520 when the warming blanket is removed from the warming cabinet. After applying the warming blanket 400 to the patient, the temperature of the PCMs 430 decreases to approximately 38 degrees Celsius at time 522. This temperature gradually decreases throughout the time period 524 to a temperature of approximately 35 degrees Celsius. After the time period 524, the temperature of the PCMs 430 exponentially decreases to a temperature of approximately 26 degrees Celsius at time 526.
Referring to line 508, the second fabric layer 442 has a temperature of approximately 54 degrees Celsius at time 520 when the warming blanket is removed from the warming cabinet. After applying the warming blanket 400 to the patient, the temperature of the second fabric layer 442 decreases to approximately 34 degrees Celsius at time 522. This temperature gradually decreases throughout the time period 524 to a temperature of approximately 30 degrees Celsius. After the time period 524, the temperature of the second fabric layer 442 exponentially decreases to a temperature of approximately 24 degrees Celsius at time 526.
Accordingly, the warming blanket 400 can maintain a temperature of the patient's skin for approximately 45 minutes before the warming blanket 400 needs to be replaced. This maintenance of temperature reduces the number of times that a caregiver has to change the patient's warming blanket 400 in comparison to other warming blankets. The warming blanket 400 maintains heat longer than conventional cotton warming blankets which lose heat in one or two minutes. Caregivers and other staff can use the warming blanket 400 without making changes to their work processes, thus enhancing the likelihood of customer adoption. The warming blanket is configured to be pre-heated in the warming cabinet along with traditional cotton warming blankets. The warming blanket 400 maintains a cotton feel and the temperature stays within a comfortable range without overheating or burning the patient. The warming blanket 400 is reusable and only one blanket is needed at a time, thereby reducing trips to the warming oven to replace cooled blankets. Additionally, a heavier weight of the warming blanket 400 provides comfort to the patient.
Although this disclosure refers to specific embodiments, it will be understood by those skilled in the art that various changes in form and detail may be made without departing from the subject matter set forth in the accompanying claims.
The present disclosure is a non-provisional patent application of, and claims priority to, U.S. Patent Application Ser. No. 62/626,877, filed Feb. 6, 2018 and titled “REUSABLE WARMING BLANKET WITH PHASE CHANGE MATERIAL” and U.S. Patent Application Ser. No. 62/718,507, filed Aug. 14, 2018 and titled “REUSABLE WARMING BLANKET WITH PHASE CHANGE MATERIAL,” both of which are herein incorporated in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4391267 | Arrhenius | Jul 1983 | A |
4504402 | Chen et al. | Mar 1985 | A |
4596250 | Beisang et al. | Jun 1986 | A |
4651369 | Guldager | Mar 1987 | A |
4667658 | Guibert | May 1987 | A |
4671267 | Stout | Jun 1987 | A |
4699134 | Samuelsen | Oct 1987 | A |
4708812 | Hatfield | Nov 1987 | A |
4756299 | Podella | Jul 1988 | A |
4807696 | Colvin et al. | Feb 1989 | A |
4911232 | Colvin et al. | Mar 1990 | A |
4914717 | Gibbon | Apr 1990 | A |
4962761 | Golden | Oct 1990 | A |
4964402 | Grim et al. | Oct 1990 | A |
4981135 | Hardy | Jan 1991 | A |
4999867 | Toivio et al. | Mar 1991 | A |
5010608 | Barnett et al. | Apr 1991 | A |
5033136 | Elkins | Jul 1991 | A |
5069208 | Noppel et al. | Dec 1991 | A |
5072455 | Thomas | Dec 1991 | A |
5088487 | Turner | Feb 1992 | A |
5094238 | Gibbon | Mar 1992 | A |
5181905 | Flam | Jan 1993 | A |
5190031 | Guibert et al. | Mar 1993 | A |
5211949 | Salyer | May 1993 | A |
5275156 | Milligan et al. | Jan 1994 | A |
5277180 | Angelillo et al. | Jan 1994 | A |
5300103 | Stempel et al. | Apr 1994 | A |
5366801 | Bryant et al. | Nov 1994 | A |
5431622 | Pyrozyk et al. | Jul 1995 | A |
5443487 | Guibert et al. | Aug 1995 | A |
5456704 | Kilcullen | Oct 1995 | A |
5456852 | Isiguro | Oct 1995 | A |
5486207 | Mahawili | Jan 1996 | A |
5511260 | Dinsmoor, III et al. | Apr 1996 | A |
5575815 | Slepian et al. | Nov 1996 | A |
5630961 | Salee | May 1997 | A |
5637389 | Colvin et al. | Jun 1997 | A |
5691040 | Barbeau et al. | Nov 1997 | A |
5702375 | Angelillo et al. | Dec 1997 | A |
5713143 | Kendall | Feb 1998 | A |
5722482 | Buckley | Mar 1998 | A |
5737774 | , I et al. | Apr 1998 | A |
5750962 | Hyatt | May 1998 | A |
5800480 | Augustine et al. | Sep 1998 | A |
5817145 | Augustine et al. | Oct 1998 | A |
5837002 | Augustine et al. | Nov 1998 | A |
5887437 | Maxim | Mar 1999 | A |
5926884 | Biggie et al. | Jul 1999 | A |
5932129 | Hyatt | Aug 1999 | A |
5964723 | Augustine | Oct 1999 | A |
5984953 | Sabin et al. | Nov 1999 | A |
5993480 | Burrows | Nov 1999 | A |
6004662 | Buckley | Dec 1999 | A |
6007572 | Baldwin | Dec 1999 | A |
6010528 | Augustine et al. | Jan 2000 | A |
6033432 | Augustine et al. | Mar 2000 | A |
6040493 | Cooke et al. | Mar 2000 | A |
6071254 | Augustine | Jun 2000 | A |
6071304 | Augustine et al. | Jun 2000 | A |
6080189 | Augustine et al. | Jun 2000 | A |
6083254 | Evans | Jul 2000 | A |
6083256 | Der Ovanesian | Jul 2000 | A |
6095992 | Augustine | Aug 2000 | A |
6102936 | Augustine et al. | Aug 2000 | A |
6113561 | Augustine | Sep 2000 | A |
6119474 | Augustine et al. | Sep 2000 | A |
6120530 | Nuckols et al. | Sep 2000 | A |
6123716 | Augustine et al. | Sep 2000 | A |
6132455 | Shang | Oct 2000 | A |
6179879 | Robinson et al. | Jan 2001 | B1 |
6183855 | Buckley | Feb 2001 | B1 |
6497720 | Augustine et al. | Dec 2002 | B1 |
6699266 | Lachenbruch et al. | Mar 2004 | B2 |
6755852 | Lachenbruch et al. | Jun 2004 | B2 |
6763671 | Klett et al. | Jul 2004 | B1 |
6772825 | Lachenbruch et al. | Aug 2004 | B2 |
6904956 | Noel | Jun 2005 | B2 |
6996864 | Call | Feb 2006 | B2 |
7043768 | Gogarty | May 2006 | B2 |
7048976 | Caceres et al. | May 2006 | B2 |
7191478 | Schmidt | Mar 2007 | B2 |
7238196 | Wibaux | Jul 2007 | B2 |
7240720 | Noel | Jul 2007 | B2 |
7273490 | Lachenbruch | Sep 2007 | B2 |
7452339 | Mattison | Nov 2008 | B2 |
7588548 | Kopreski | Sep 2009 | B2 |
7708338 | Wolas | May 2010 | B2 |
7727267 | Lachenbruch | Jun 2010 | B2 |
7766950 | Castellani et al. | Aug 2010 | B2 |
7780713 | Roberts | Aug 2010 | B2 |
7793372 | Lean et al. | Sep 2010 | B2 |
7854754 | Ting et al. | Dec 2010 | B2 |
8002721 | Bretl et al. | Aug 2011 | B2 |
8062343 | Augustine et al. | Nov 2011 | B2 |
8065763 | Brykalski et al. | Nov 2011 | B2 |
8100848 | Wilkes et al. | Jan 2012 | B2 |
8129580 | Wilkes et al. | Mar 2012 | B2 |
8133211 | Cavanaugh, II et al. | Mar 2012 | B2 |
8147468 | Barta et al. | Apr 2012 | B2 |
8167856 | Kazala, Jr. et al. | May 2012 | B2 |
8172816 | Kazala, Jr. et al. | May 2012 | B2 |
8181290 | Brykalski et al. | May 2012 | B2 |
8187237 | Seegert | May 2012 | B2 |
8188331 | Barta et al. | May 2012 | B2 |
8191187 | Brykalski et al. | Jun 2012 | B2 |
8192474 | Levinson | Jun 2012 | B2 |
8202261 | Kazala, Jr. et al. | Jun 2012 | B2 |
8241261 | Randolph et al. | Aug 2012 | B2 |
8275442 | Allison | Sep 2012 | B2 |
8277497 | Noel | Oct 2012 | B2 |
8285390 | Levinson et al. | Oct 2012 | B2 |
8292936 | Jung | Oct 2012 | B2 |
8292937 | Von Hoffmann et al. | Oct 2012 | B2 |
8303857 | Seeboth et al. | Nov 2012 | B2 |
8326426 | Thornton et al. | Dec 2012 | B2 |
8327477 | Lachenbruch et al. | Dec 2012 | B2 |
8332975 | Brykalski et al. | Dec 2012 | B2 |
8337539 | Ting et al. | Dec 2012 | B2 |
8376232 | Eckstein et al. | Feb 2013 | B2 |
8399730 | Kazala, Jr. et al. | Mar 2013 | B2 |
8402579 | Marquette et al. | Mar 2013 | B2 |
8418286 | Brykalski et al. | Apr 2013 | B2 |
8603073 | Mlison | May 2013 | B2 |
8523927 | Levinson et al. | Sep 2013 | B2 |
8528833 | Munson | Sep 2013 | B2 |
8578527 | Lachenbruch et al. | Nov 2013 | B2 |
8617230 | Diller et al. | Dec 2013 | B2 |
8621687 | Brykalski et al. | Jan 2014 | B2 |
8641745 | Warner et al. | Feb 2014 | B2 |
8673448 | Hartmann et al. | Mar 2014 | B2 |
8702774 | Baker et al. | Apr 2014 | B2 |
8722959 | Wilkes et al. | May 2014 | B2 |
8732874 | Brykalski et al. | May 2014 | B2 |
8782830 | Brykalski et al. | Jul 2014 | B2 |
8800078 | Lachenbruch et al. | Aug 2014 | B2 |
8856993 | Richards et al. | Oct 2014 | B2 |
8858971 | Rao | Oct 2014 | B2 |
8887619 | Kallmyer et al. | Nov 2014 | B2 |
8893329 | Petrovski et al. | Nov 2014 | B2 |
8933140 | Peterson et al. | Jan 2015 | B2 |
8937212 | Fogg et al. | Jan 2015 | B2 |
9009892 | Lachenbruch et al. | Apr 2015 | B2 |
9084764 | Rao | Jul 2015 | B2 |
9089462 | Lafleche | Jul 2015 | B1 |
9125497 | Brykalski et al. | Sep 2015 | B2 |
9132031 | Levinson et al. | Sep 2015 | B2 |
9158141 | DeFranks | Oct 2015 | B2 |
9234059 | Hartmann et al. | Jan 2016 | B2 |
9265654 | Gallaher | Feb 2016 | B2 |
9326882 | Moulin | May 2016 | B2 |
9333136 | Gibson et al. | May 2016 | B2 |
9339412 | Diller et al. | May 2016 | B2 |
9375345 | Levinson et al. | Jun 2016 | B2 |
9408475 | Mikkelsen et al. | Aug 2016 | B2 |
20010039391 | Augustine | Nov 2001 | A1 |
20020086204 | Rock | Jul 2002 | A1 |
20030046762 | Stolpmann | Mar 2003 | A1 |
20030109816 | Lachenbruch et al. | Jun 2003 | A1 |
20030109908 | Lachenbruch et al. | Jun 2003 | A1 |
20030109910 | Lachenbruch et al. | Jun 2003 | A1 |
20050049662 | Purcell | Mar 2005 | A1 |
20050076715 | Kuklis et al. | Apr 2005 | A1 |
20050145372 | Noel | Jul 2005 | A1 |
20060100682 | Koffroth | May 2006 | A1 |
20060184216 | Van Duren | Aug 2006 | A1 |
20060260058 | Schmidt | Nov 2006 | A1 |
20060276089 | Amarasinghe et al. | Dec 2006 | A1 |
20070098973 | Wagner et al. | May 2007 | A1 |
20070101478 | Koscheyev et al. | May 2007 | A1 |
20070135878 | Lachenbruch et al. | Jun 2007 | A1 |
20070173154 | Hartmann et al. | Jul 2007 | A1 |
20070193278 | Polacek et al. | Aug 2007 | A1 |
20070198071 | Ting et al. | Aug 2007 | A1 |
20070250025 | Sams et al. | Oct 2007 | A1 |
20070255362 | Levinson et al. | Nov 2007 | A1 |
20080015665 | Lachenbruch | Jan 2008 | A1 |
20080028517 | Schmidt | Feb 2008 | A1 |
20080077201 | Levinson et al. | Mar 2008 | A1 |
20080120761 | Yang et al. | May 2008 | A1 |
20080140166 | von Hoffman et al. | Jun 2008 | A1 |
20080234789 | Freeland et al. | Sep 2008 | A1 |
20090018623 | Levinson et al. | Jan 2009 | A1 |
20090018624 | Levinson et al. | Jan 2009 | A1 |
20090018625 | Levinson et al. | Jan 2009 | A1 |
20090018626 | Levinson et al. | Jan 2009 | A1 |
20090018627 | Levinson et al. | Jan 2009 | A1 |
20090076574 | Noel | Mar 2009 | A1 |
20090076575 | Noel | Mar 2009 | A1 |
20090293887 | Wilkes et al. | Dec 2009 | A1 |
20090299249 | Wilkes et al. | Dec 2009 | A1 |
20090299256 | Barta et al. | Dec 2009 | A1 |
20090299307 | Barta et al. | Dec 2009 | A1 |
20090299308 | Kazala, Jr. et al. | Dec 2009 | A1 |
20090299442 | Vergona et al. | Dec 2009 | A1 |
20100011489 | Goldmann et al. | Jan 2010 | A1 |
20100012883 | Hartmann et al. | Jan 2010 | A1 |
20100015430 | Hartmann et al. | Jan 2010 | A1 |
20100016513 | Hartmann et al. | Jan 2010 | A1 |
20100089381 | Bolmer et al. | Apr 2010 | A1 |
20100227542 | Goldmann et al. | Sep 2010 | A1 |
20100263128 | Lean et al. | Oct 2010 | A1 |
20100274331 | Williamson et al. | Oct 2010 | A1 |
20100280582 | Baker et al. | Nov 2010 | A1 |
20110024076 | Lachenbruch et al. | Feb 2011 | A1 |
20110041780 | Hurwitz | Feb 2011 | A1 |
20110092890 | Stryker et al. | Apr 2011 | A1 |
20110127248 | Moreshead | Jun 2011 | A1 |
20110128686 | Moreshead | Jun 2011 | A1 |
20110128726 | Moreshead | Jun 2011 | A1 |
20110130813 | Moreshead | Jun 2011 | A1 |
20110183712 | Eckstein et al. | Jul 2011 | A1 |
20120023664 | Joo et al. | Feb 2012 | A1 |
20120095538 | Dow | Apr 2012 | A1 |
20120180225 | Gladney et al. | Jul 2012 | A1 |
20120330213 | Valdez | Dec 2012 | A1 |
20130043232 | Whitworth et al. | Feb 2013 | A1 |
20130205462 | Kitaura et al. | Aug 2013 | A1 |
20130296769 | Howell et al. | Nov 2013 | A1 |
20140141233 | Crawford et al. | May 2014 | A1 |
20140221962 | Ribble et al. | Aug 2014 | A1 |
20140266643 | Receveur et al. | Sep 2014 | A1 |
20140304915 | Lachenbruch | Oct 2014 | A1 |
20140359939 | Carlitz | Dec 2014 | A1 |
20150013073 | Schwirian et al. | Jan 2015 | A1 |
20160235210 | Lachenbruch et al. | Aug 2016 | A1 |
Number | Date | Country |
---|---|---|
2175398 | Apr 2010 | EP |
1635757 | Jun 2010 | EP |
2272473 | Jan 2011 | EP |
1895874 | May 2012 | EP |
2276437 | Dec 2012 | EP |
2594234 | May 2013 | EP |
2344988 | Aug 2013 | EP |
2702966 | Mar 2014 | EP |
2643814 | Sep 1990 | FR |
2867672 | Sep 2005 | FR |
2510154 | Jul 2014 | GB |
2514594 | Dec 2014 | GB |
0212607 | Feb 2002 | WO |
2005006896 | Jan 2005 | WO |
2005016074 | Feb 2005 | WO |
2005067837 | Jul 2005 | WO |
2006001980 | Jan 2006 | WO |
2006122555 | Nov 2006 | WO |
2006122556 | Nov 2006 | WO |
2007133839 | Nov 2007 | WO |
2009046155 | Apr 2009 | WO |
2010075293 | Jul 2010 | WO |
2012174276 | Dec 2012 | WO |
2013177148 | Nov 2013 | WO |
2014008182 | Jan 2014 | WO |
2014035792 | Mar 2014 | WO |
2014182767 | Nov 2014 | WO |
2015006407 | Jan 2015 | WO |
2015137999 | Sep 2015 | WO |
2015188956 | Dec 2015 | WO |
Entry |
---|
US 6,645,236 B2, 11/2003, Lachenbruch et al. (withdrawn) |
US 8,435,230 B2, 05/2013, Mlison (withdrawn) |
US 9,398,814 B2, 07/2016, Richards et al. (withdrawn) |
Extended European Search Report for Application No. 19155109.2, dated Jun. 4, 2019, 7 pages. |
Number | Date | Country | |
---|---|---|---|
20190240066 A1 | Aug 2019 | US |
Number | Date | Country | |
---|---|---|---|
62718507 | Aug 2018 | US | |
62626877 | Feb 2018 | US |